The aim of this study was to find signature CNA sequences from patients with breast cancer (BCa) or prostate cancer (PCa) compared to healthy controls, with respect to their predictive potential, as well as to provide new insights into tumor biology.
Circulating nucleic acids (CNA) isolated from serum or plasma are increasingly recognized as biomarkers for cancers.We report specific DNA-transposable element sequences that could discriminate all stages of invasive ductal breast carcinoma with significant specificity and sensitivity.
Circulating nucleic acids (CNAs) have been shown to have diagnostic utility in human diseases. The use of mass sequencing and bioinformatics provides the basis for new diagnostic approaches that use CNAs as biomarkers for both malignant and nonmalignant diseases.
In a 25-month time-course experiment, CNAs were isolated from blood samples of 24 elk (Cervuselaphus) orally challenged with chronic wasting disease (CWD) infectious material.Our results may become useful for the early diagnosis of TSE in live elk and cattle.
Advanced PDAC is a lethal disease with dismal 5 year survival. The current modalities for monitoring therapy response using serum (CA) 19-9 levels have poor specificity and radiological responses have long lag times. Tests for rapid and accurate clinical assessment are needed for early decision making.
Tumor derived plasma cell-free DNA (TcfDNA) is described as biomarker to monitor tumor burden in cancer. Large somatic genome aberrations are hallmarks of malignancies and detectable in cfDNA. However, levels of TcfDNA are variable according to cancer types. We obtained copy-number instability (CNI) scores of cfDNA in treatment-naïve head and neck cancers before and after therapy.